05/13/2019/by jcalhoonPoseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
05/13/2019/by jcalhoonPoseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
02/13/2019/by poseida superPoseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks
01/04/2019/by poseida superPoseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions
12/03/2018/by jnellisPoseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
11/29/2018/by jcalhoonPoseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting
11/05/2018/by jcalhoonPoseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101
10/09/2018/by jcalhoonPoseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs
09/05/2018/by jcalhoonPoseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
08/29/2018/by jcalhoonPoseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018
